About This Reference Desk

What Get Peptides USA is

Get Peptides USA is an independent editorial reference desk covering the published research on three peptides studied for the GH/IGF-1 axis and body composition: ipamorelin (the lead), tesamorelin, and MOTS-c. The site exists to make a complicated, overstated, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence reaches.

The organizing idea is the GH/IGF-1 axis: the endocrine cascade running from the hypothalamus through the pituitary and into peripheral tissues, governing growth, body composition, and metabolic homeostasis. The three compounds on this desk approach that axis from different angles — GHRH-receptor stimulation, ghrelin-receptor stimulation, and mitochondrial AMPK activation — which is why reading them together gives a clearer picture of the research landscape than any single compound alone.

Each compound has its own dedicated page. A comparison page lines all three up side by side. A single shared references list aggregates every source used across the desk.

Editorial method

Content on this desk is compiled from peer-reviewed literature: primary research articles, clinical trials, systematic reviews and meta-analyses, and authoritative regulatory and pharmacological monographs. All cited sources are listed in the references index with DOIs or PubMed links wherever available. Every in-text citation, listed as a bracketed number, maps directly to a verifiable source in that index.

The editorial process applies a consistent standard across every compound page:

• Species specificity. Where a finding comes from rats, mice, or cell cultures, that is stated explicitly. Human findings are labeled with study type (RCT, observational, PK study) and sample size.
• Evidence strength. Weak, preliminary, or single-lab findings are flagged as such. A single rodent study from one research group is not presented with the same weight as a replicated randomized controlled trial.
• Regulatory accuracy. Approval status, WADA prohibition status, and compounding eligibility are verified against the original regulatory sources, not secondary references. Tesamorelin's approval is described with its exact indication and population; ipamorelin's failed Phase 2 and 2024 503A removal are stated directly.
• No fabricated citations. Every reference was included because it was verified to exist; no PMIDs, DOIs, or citations are generated from inference or extrapolation.
• No dosing, no medical advice. Doses mentioned on this desk are reported exactly as they appeared in the study cited — never as a recommended protocol.

What this desk is not

Get Peptides USA is not affiliated with any supplier, manufacturer, clinic, or commercial entity selling research peptides or pharmaceutical products. It has no paid partnerships or sponsorship relationships with any compound manufacturer. It receives no financial benefit from any decisions a reader makes about purchasing or using any substance.

It is not a medical or clinical practice. Nothing on this site constitutes medical advice, a diagnosis, a treatment recommendation, or a prescription. Nothing on this site is a substitute for consultation with a qualified healthcare provider.

It does not endorse the use of any compound outside of its approved indications. Where a compound is approved only for a specific population (tesamorelin, HIV lipodystrophy), that scope is stated clearly. Where a compound has no approval at all (ipamorelin, MOTS-c), that is stated clearly.

It does not have a fake author, fake credentials, a fake clinical team, or a fake address. It is an editorial reference desk, and that is all it is.